Dechra Announces FDA Approval of Emeprev™ (maropitant citrate) Injectable Solution

Audio By Carbonatix

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dec 8, 2025--

Dechra, a global leader in veterinary specialty care, today shares the FDA approval of Emeprev™ (maropitant citrate) Injectable Solution, the first FDA-approved bioequivalent injectable solution to the most widely used antiemetic for dogs and cats. 1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208087531/en/

Dechra's new bioequivalent provides veterinarians with an in-clinic antiemetic option to support patient relief from vomiting and helping to ensure clinical confidence.

Indicated for the prevention and treatment of acute vomiting in dogs and the treatment of vomiting in cats, Emeprev™ sets a new standard for patient and clinic experience:

• Differentiated Preservative for Comfort: Emeprev™ contains benzyl alcohol, a preservative demonstrated to act as a local anesthetic and reduce pain during injection in healthy laboratory dogs. 2 In a study of healthy laboratory dogs, subcutaneous injection of Emeprev™ was significantly less painful than the pioneer drug. 2
• Simple Storage: Emeprev™ requires no refrigeration, streamlining clinic operations and making it easier for veterinary teams to deliver care without added logistical challenges.

Trusted Effectiveness, Now with a New Option

“Emeprev™ delivers the same trusted antiemetic effectiveness as the pioneer with a different preservative. It's a win for our patients and their caregivers,” said Dr. Christopher Byers, DVM, DACVECC, DACVIM (SAIM), CVJ, a Key Opinion Leader for Dechra.

A Leading Solution for Vomiting in Dogs and Cats

Maropitant is the most used medication for vomiting in dogs and cats 1, and Emeprev™ Injectable Solution is the first FDA-approved bioequivalent maropitant injectable solution, providing veterinarians with a reliable, in-clinic option to support patient relief from vomiting and helping to ensure clinical confidence.

“The introduction of Emeprev™ Injectable Solution builds on our continued commitment to providing veterinarians with high-quality, practical solutions they can trust,” said Laura Olsen, President, North America, and Chief Marketing Officer, Dechra. “We’re focused on expanding our companion-animal portfolio with products that address real-world clinical needs and strengthen the human–animal bond.”

Availability

Emeprev™ will be available for order through all major veterinary distributors in early 2026.

About Emeprev ™ (maropitant citrate) Injectable Solution

Emeprev™ Injectable Solution is indicated for the prevention and treatment of acute vomiting in dogs and for the treatment of vomiting in cats. Each mL of solution contains 10 mg maropitant (as maropitant citrate), 63 mg sulfobutylether-β-cyclodextrin, 11.1 mg benzyl alcohol (preservative), and water for injection.¹ Emeprev™ is supplied in a 20 mL amber glass vial.

Emeprev™ can be administered subcutaneously or intravenously (subcutaneous only for dogs 2 to 4 months of age).

Important Safety Information

As with all drugs, side effects may occur. Use Emeprev Injectable for vomiting in cats 4 months and older; use subcutaneously for acute vomiting in dogs 2 to 4 months of age or either subcutaneously or intravenously in dogs 4 months of age and older. Safe use has not been evaluated in cats and dogs with gastrointestinal obstruction, or those that have ingested toxins. Use with caution in cats and dogs with hepatic dysfunction. Pain/vocalization upon injection is a common side effect. In people, topical exposure may elicit localized allergic skin reactions, and repeated or prolonged exposure may lead to skin sensitization. Refer to the prescribing information for complete details or visit www.dechra‐us.com.

To obtain a full Safety Data Sheet, contact Dechra at 1-866-933-2472.

About Dechra

Dechra is a global specialist in veterinary pharmaceuticals and related products, dedicated to supporting veterinarians, pet owners, and the animals they care for. For more information, visit www.dechra-us.com.

References

1. Data on file.
2. Deckers N, Ruigrok CA, Verhoeve HP, et al. Veterinary Record Open 2018;5:e000262. doi:10.1136 Pain scored by VAS & SDS. Prevomax and Emeprev have identical formulations.

This communication may contain information about a product that is otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.

© 2025, Dechra Veterinary Products LLC., all rights reserved. Dechra Is a registered trademark of Dechra Pharmaceuticals Limited. Prevomax and Emeprev™ are trademarks of Dechra Limited or its affiliates. C250762

View source version on businesswire.com:https://www.businesswire.com/news/home/20251208087531/en/

CONTACT: Media Contact:

Lauren Dorsch

Tel: 913-914-6903

Email: [email protected]

www.dechraus.com

@DechraUS

www.facebook.com/dechraus

KEYWORD: KANSAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL PETS HEALTH FDA CONSUMER

SOURCE: Dechra

Copyright Business Wire 2025.

PUB: 12/08/2025 08:00 AM/DISC: 12/08/2025 08:02 AM

http://www.businesswire.com/news/home/20251208087531/en